Use of beta-glucans against biological warfare weapons and pathogens including anthrax
The present invention provides a means to broadly protect the military and the public from injury from biological warfare weapons, particularly infective agents such as anthrax. Beta (1,3)-glucans, particularly whole glucan particles, PGG-Glucan, and microparticulate glucan, provide general immune enhancement, thereby increasing the body's ability to defend against a wide variety of biological threats. Beta (1,3)-glucans have been shown to increase the resistance to infection by anthrax and other infectious organisms when administered before and after infection. The anti-infective mechanism of β(1,3)-glucan appears to involve stimulation of the innate immune system through increased cytokine release and CR3 receptor activation. Beta (1,3)-glucan is pharmaceutically stable, relatively compact, and can also be used without significant side effects. Beta (1,3)-glucan can also enhance the effectiveness of other medical countermeasures such as antibiotics, vaccines, and immune antibodies.
1. A method consisting essentially of administering to a human in need of protection against infection by Bacillus anthracis an effective amount of underivatized, particulate β(1,3)-Glucan, wherein the human is a soldier or a health worker.
2. The method of claim 1 , further comprising poly-(1,6)-β-D-glucopyranosyl-(1,3)-β-D-glucopyranose (PGG) glucan.
3. The method claim 1 , wherein said β(1,3)-Glucan comprises whole glucan particles.
4. The method of claim 1 , wherein said β(1,3)-Glucan comprises a combination of poly-(1,6)-β-D-glucopyranosyl-(1,3)-β-D-glucopyranose (PGG) glucan and whole glucan particles.
5. The method of claim 2 , wherein about 0.1-100 mg/Kg of poly-(1,6)-β-D-glucopyranosyl-(1,3)-β-D-glucopyranose (PGG) glucan is administered daily.
6. The method of claim 3 , wherein greater than 0.01 mg/Kg of whole glucan particles is administered daily.
7. The method of claim 4 , wherein a combination of about 0.1-100 mg/Kg of poly-(1,6)-β-D-glucopyranosyl-(1,3)-β-D-glucopyranose (PGG) and about 0.1-500 mg/Kg of whole glucan particles is administered daily.
8. The method of claim 2 , wherein about 1-10 mg/Kg of poly-(1,6)-β-D-glucopyranosyl-(1,3)-β-D-glucopyranose (PGG) is administered daily.
9. The method claim 3 , wherein about 10 mg/Kg of whole glucan particles is administered daily.
10. The method of claim 4 , wherein a combination of about 1-10 mg/Kg of poly-(1,6)-β-D-glucopyranosyl-(1,3)-β-D-glucopyranose (PGG) and about 2-20 mg/Kg of whole glucan particles is administered daily.
11. The method of claim 1 , wherein the β(1,3)-Glucan is administered orally, topically, subcutaneously, intramuscularly, transdermally, intradermally, intravenously, or through the gastrointestinal tract.
12. The method of claim 1 , wherein the β(1,3)-Glucan is administered orally.